Axsome v. Aurobindo: 8-Patent Solriamfetol Dispute Consolidated in New Jersey
Axsome Malta and Axsome Therapeutics filed suit against Aurobindo Pharma over eight U.S. patents covering solriamfetol oral tablets (75 mg and 150 mg base). The case was resolved procedurally after just 64 days when it was folded into a consolidated multi-action proceeding alongside seven related cases in the District of New Jersey.
Eight-Patent ANDA Fight Over Solriamfetol Folded Into Broader Action
On 19 March 2024, Axsome Malta, Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-04002 in the U.S. District Court for the District of New Jersey, asserting infringement of eight U.S. patents directed to solriamfetol oral tablet formulations at 75 mg and 150 mg base equivalents. The defendant, Aurobindo Pharma Ltd. and its U.S. entity Aurobindo Pharma Limited, Inc., is a generic pharmaceutical manufacturer whose ANDA filing for a solriamfetol generic product triggered the Hatch-Waxman litigation.
On 22 May 2024 — just 64 days after filing — the court ordered this case consolidated for all purposes, including discovery, case management, and trial, with seven other related civil actions (Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-3999, and 24-4608) into a single Consolidated Action. No merits ruling was issued; the case was administratively closed as part of this procedural reorganisation. The substantive patent infringement dispute continues under the umbrella of the consolidated proceeding.
The 64-day timeline before consolidation is consistent with standard Hatch-Waxman case management practice in New Jersey, where courts routinely consolidate related ANDA suits against the same branded product early to promote efficiency. The breadth of the consolidated docket — spanning at least eight separate civil actions — suggests Axsome has pursued an aggressive enforcement campaign across multiple generic filers. What remains unknown from the public record in this specific docket is the identity of all defendants in the consolidated proceeding and the current trial schedule.
Filing to Case Consolidated in 64 days
64 days from filing to consolidation — procedurally resolved before discovery began
Case consolidated: what the court order means for both parties
Consolidation merges cases — litigation does not end
Under Federal Rule of Civil Procedure 42(a), a court may consolidate actions involving a common question of law or fact. Here, the court consolidated eight related ANDA infringement cases into a single proceeding for discovery, case management, and trial. This is a procedural step, not a merits ruling — the patent infringement claims remain live and will be adjudicated together in the Consolidated Action.
FRCP 42(a) consolidationAxsome retains all infringement claims going forward
Consolidation does not prejudice Axsome’s position. All eight patents asserted in this docket carry forward into the Consolidated Action. Axsome may benefit from consolidated discovery efficiencies and a unified trial strategy against multiple generic filers. The breadth of the patent portfolio asserted — eight patents covering solriamfetol formulations — signals a layered enforcement approach designed to maximise litigation leverage.
Claims preserved; enforcement continuesAurobindo faces consolidated litigation with wider defendant field
Aurobindo now litigates within a consolidated proceeding that encompasses multiple civil actions, potentially involving other generic filers challenging the same Axsome patents. This typically means shared discovery burdens and coordinated scheduling, which can benefit a well-resourced generic challenger. However, the consolidated forum also concentrates Axsome’s enforcement resources, potentially strengthening the brand holder’s litigation posture.
Consolidated multi-defendant proceedingSolriamfetol generic entry remains blocked pending trial outcome
Under Hatch-Waxman, the filing of suit within 45 days of an ANDA paragraph IV certification triggers an automatic 30-month stay of FDA approval for the generic product. With eight patents asserted and the case now in a consolidated proceeding, Aurobindo’s solriamfetol generic tablets at 75 mg and 150 mg base remain blocked from market entry until the stay expires or the patents are adjudicated. The consolidated action’s trial timeline will be determinative for generic market entry.
30-month stay likely in effectFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma Limited, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | WILLIAM HARE | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | McNeely, Hare & War LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s consolidation order does not resolve any claim on the merits. The directive to consolidate Civil Action Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-3999, 24-4002, and 24-4608 ‘for all purposes, including discovery, case management, and trial’ signals that the court views these actions as sufficiently related — likely because they share the same branded drug, overlapping patent claims, and analogous ANDA challenges. Both parties retain their positions; Axsome’s infringement claims and Aurobindo’s invalidity and non-infringement defences will be adjudicated in the consolidated proceeding.
US11839598B2 and 7 further patents — solriamfetol oral tablet formulations
The eight asserted patents — US11839598B2, US11865098B1, US11872204B1, US11850226B2, US11857528B1, US11872203B1, US11850228B2, and US11850227B2 — all relate to solriamfetol, a dopamine and norepinephrine reuptake inhibitor approved for treating excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnoea, marketed as Sunosi. The patents are recent grants, with corrected application numbers suggesting prosecution timelines in 2023, making them relatively fresh assets in Axsome’s portfolio following its acquisition of the solriamfetol programme.
Strategically, the cluster of eight patents covering solriamfetol oral tablet formulations at 75 mg and 150 mg base represents a deliberate effort to create a dense intellectual property thicket around a commercially significant CNS product. The pattern of multiple continuation or divisional applications — suggested by the overlapping application number series — is consistent with a prosecution strategy designed to generate independent patent term and claim coverage across formulation, dosing, and method dimensions, maximising the barrier to generic entry and extending effective market exclusivity beyond any single patent’s expiry.
Should you run an FTO against the Axsome solriamfetol patent portfolio?
Any pharmaceutical company developing oral tablet formulations of solriamfetol, or structurally related dopamine/norepinephrine reuptake inhibitors targeting wakefulness or attention indications, should treat Axsome’s eight-patent portfolio as a live FTO risk. This applies not only to ANDA filers seeking generic approval of Sunosi equivalents but also to 505(b)(2) applicants and any R&D programme developing solriamfetol-based or closely analogous CNS agents in the same dosage form and therapeutic range.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map each of the eight asserted patents against candidate product profiles — analysing claim scope, prosecution history, and potential design-arounds in a fraction of the time of traditional FTO workflows. With a consolidated trial pending in New Jersey and multiple generic challengers already engaged, the competitive and litigation landscape around solriamfetol oral tablets is moving fast. Eureka’s real-time docket monitoring and patent landscape tools help you stay ahead of enforcement risk.
Run a freedom-to-operate analysis on US11839598B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases: solriamfetol and CNS drug patents
Related ANDA patent infringement cases involving solriamfetol formulation patents and CNS wakefulness drugs litigated in the District of New Jersey.
What this case signals for the pharmaceutical ANDA IP landscape
Axsome’s eight-patent assertion against a single ANDA filer reflects a maturing enforcement strategy common among branded CNS drug developers.
Multi-patent stacking is now standard ANDA defence practice
Asserting eight patents against a single generic filer — covering formulation, dosage, and method claims — is a deliberate strategy to multiply invalidity and non-infringement hurdles for the generic challenger. Any single surviving patent can maintain the 30-month stay. Branded pharma companies in the CNS space should audit their formulation patent portfolios for similar layering opportunities.
New Jersey consolidation signals high-volume ANDA campaign by Axsome
With at least eight consolidated civil actions, Axsome is simultaneously defending against multiple generic challengers. This concentration in New Jersey’s District Court — a preferred ANDA venue — suggests a coordinated enforcement strategy. Generic entrants and their investors should monitor the consolidated docket closely for scheduling orders and any inter partes review filings that could accelerate patent validity decisions.
Axsome v Aurobindo — key questions answered
The case was filed on 19 March 2024 and closed on 22 May 2024 after the New Jersey District Court consolidated it with seven related ANDA infringement actions into a single Consolidated Action. No merits ruling was issued. The patent infringement claims over solriamfetol oral tablets continue in the consolidated proceeding.
Axsome asserted eight U.S. patents: US11839598B2, US11865098B1, US11872204B1, US11850226B2, US11857528B1, US11872203B1, US11850228B2, and US11850227B2, all directed to solriamfetol oral tablet formulations at 75 mg and 150 mg base equivalents, corresponding to the branded product Sunosi.
Consolidation under FRCP 42(a) means this case was merged with seven related ANDA actions for all purposes — discovery, case management, and trial. The infringement claims are not dismissed; they continue in the consolidated proceeding. Neither party gained or lost any substantive right as a result of consolidation.
The case data does not confirm the exact stay trigger date or expiry, but the filing of an ANDA infringement suit within 45 days of a paragraph IV certification typically triggers an automatic 30-month FDA approval stay for the generic product. With the case now in consolidated litigation, the stay and trial timeline will determine when — if ever — Aurobindo’s solriamfetol generic can reach market.
Potentially yes. IPR petitions must generally be filed within one year of service of an infringement complaint. Given the 2024 filing dates, some petition windows may still be open for defendants in the consolidated action. A successful IPR on any of the eight asserted patents could materially affect both the litigation and the 30-month stay, making IPR strategy a critical consideration for Aurobindo and co-defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.